Santaris Pharma is a clinical-stage biopharmaceutical company founded in 2003, headquartered in Denmark, and operating in the United States. The company specializes in pioneering RNA-targeted therapies with rapid LNA-based drug development for diverse disease states. Santaris Pharma's proprietary LNA Drug Platform and Drug Discovery Engine integrate advanced LNA chemistry with focused drug development capabilities to efficiently produce potent single-stranded LNA-based drug candidates.
The company's R&D efforts primarily target infectious diseases and cardiometabolic disorders, with key collaborations in therapeutic areas like cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. Notable partnerships include miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals.
With a $12.00M Venture Round investment on 21 June 2012, Santaris Pharma attracted funding from prominent investors such as Novo Holdings, Seventure Partners, Sunstone Capital, Forbion, Gilde Healthcare, and Global Life Science Ventures.
With its unique focus on RNA-targeted therapies and strong collaborations, Santaris Pharma presents an intriguing proposition for venture capitalists looking to invest in the biotechnology, healthcare, and pharmaceutical industries.
